Iodine-131 tositumomab (Bexxar) in a radiation oncology environment

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue SUPPL. 2, 2006, Pages

  Macklis, Roger M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bexxar; Iodine 131 tositumomab; Non Hodgkin's lymphoma

Indexed keywords

CELLS; IMMUNOLOGY; MEDICAL APPLICATIONS; ONCOLOGY; PATIENT TREATMENT; TOXICITY;

BEXXAR; IODINE-131 TOSITUMOMAB; NON-HODGKIN'S LYMPHOMA;

ANTIBODIES;

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G2A; MEMBRANE ANTIGEN; POTASSIUM IODIDE; RITUXIMAB; TOSITUMOMAB I 131;

ACUTE LEUKEMIA; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; EPITHELIUM TUMOR; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYPOTHYROIDISM; ISOTOPE LABELING; LEUKOPENIA; LUNG CANCER; MELANOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; ONCOLOGY; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; RADIATION RESPONSE; RADIATION SAFETY; RADIOIMMUNOTHERAPY; SKIN CANCER; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; METABOLIC CLEARANCE RATE; MULTICENTER STUDIES; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIATION ONCOLOGY; RADIOIMMUNOTHERAPY;

EID: 33748460262     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.06.002     Document Type: Article

References (17)

1. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14 (1996) 1974-1981
2. Shan D., Ledbetter J.A., and Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91 (1998) 1644-1652
3. Cardarelli P.M., Quinn M., Buckman D., et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 51 (2002) 15-24
4. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
5. Dillman R.O. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 20 (2002) 3545-3557
6. Hernandez M.C., and Knox S.J. Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 59 (2004) 1274-1287
7. Cheson B.D. Radioimmunotherapy for non-Hodgkin's lymphoma. Blood 101 (2003) 391-398
8. Sgouros G., Squeri S., Ballangrud A., et al. Patient-specific, 3 dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131-I-anti-B1 antibody: Assessment of tumor dose-response. J Nucl Med 44 (2003) 260-268
9. Kaminski M.S., Fig L.M., Zasadny K.R., et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10 (1992) 1696-1711
10. Loevinger R., Budinger T.F., and Watson E.E. MIRD primer for absorbed dose calculations (1988), The Society of Nuclear Medicine, Reston, VA
11. Wahl R.L., Kroll S., and Zasadny K.R. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 39 (1988) 14S-20S
12. Gokhale A.S., Mayadev J., Pohlman B., et al. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 194-201
13. Horning S.J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23 (2005) 712-719
14. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. N Engl J Med 329 (1993) 459-465
15. Kaminski M.S., Estes J., Zasadny K.R., et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96 (2000) 1259-1266
16. 131I-toxitumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (2005) 441-449
17. Macklis R.M. How and why does radioimmunotherapy work?. Int J Radiat Oncol Biol Phys 59 (2004) 1269-1271